Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose

Inclusion Criteria: * Agree to all the purposes of the study by signing and dating the Informed Consent; * Male, aged between 18 and 55 years, clinically healthy; * BMI between 18.5 and 30; Exclusion Criteria: * Participation in clinical trials in the 12 months preceding the trial; * Presence of pulmonary, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems diseases; * Acute disease in the period of 07 days before the beginning of the practical phase (administration of the drug) of the study; * Chronic administration of medications for hypertension, diabetes or any other disease that requires continuous use of any drug; * Hemoglobin \< 13 g/dL; * Continuous use of oral anticoagulants, platelet inhibitors or anti-inflammatory drugs; * Use of medications that interact with enoxaparin; * History of gastrointestinal bleeding, deep vein thrombosis or pulmonary embolism that may interfere with the clinical outcome of the study; * History of coagulopathy and bleeding diathesis; * Presence of changes in physical examination suggestive of coagulation disorders (bruising, petechiae, or bruising); * Changes in the skin or subcutaneous tissue of the place of drug administration(eg liposuction in the abdomen); * Absolute platelet count below 100 x 109 / L; * History of chronic bleeding; * History of acute haemorrhage in the past 30 days; * History of sensitivity to mammalian-derived biological products, albumin or any component of the formulation; * History of allergy or Steven Johnson disease; * Current or previous history (under 12 months) use of illicit drugs and tobacco; * History of alcohol abuse, current or previous (within 12 months); * At the discretion of the Principal Investigator of the study.